It's not
in time for this summer's sport season, but tennis elbow may have met
its match in platelet-rich plasma, a key component in a new "bi ologic
treatment" being studied by Allan Mishra, an orthopedic surgeon at Menlo
Clinic.
Mishra
announced his findings concerning the use of platelet-rich plasma for
this common ailment last February at the annual meeting of the American
Academy of Orthopedic Surgeons. A broader FDA-sanctioned clinical trial
is expected to begin in late summer or early fall, Mishra said.
Mishra
evaluated the use of platelet-rich plasma in patients with chronic,
severe tennis elbow who were considering surgery.
The surgeon
said that eight weeks after treatment with platelet-rich plasma - the
body's "natural ingredients" - patients' pain decreased by 60 percent
vs. 16 percent in control patients. After six months, the platelet-rich
plasma patients' pain had diminished by an average of 81 percent.
For more
information, visit www.emedx.com

An
injection may someday substitute for more invasive surgery using an
innovative injection treatment currently being evaluated by Menlo Clinic
orthopedic surgeon Allan Mishra.